{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib: Orally, once daily. Binimetinib: Orally, twice daily. Cetuximab: Standard of care.","id":"OG000","title":"Combined Safety Lead-in (CSLI)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The dose-determining set (DDS) consisted of all CSLI participants from the safety set who either completed a minimum exposure requirement (received \\>= 75% dose intensity of the planned dose for each binimetinib, encorafenib and cetuximab) and had sufficient safety evaluations or experienced a dose-limiting toxicity (DLT).","reportingStatus":"POSTED","timeFrame":"Cycle 1 (up to 28 days)","title":"(Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}